CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 23 enrolled
Drug / intervention
levodopa carbidopa and entacapone (LCE) +1 moredrug
Likely dose
levodopa carbidopa and entacapone (LCE) 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01468012
NCT01468012Phase 3Completed

Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence

New York State Psychiatric Institute·interventional·Posted Nov 9, 2011·Updated May 22, 2018

In Brief

A Phase 3 clinical trial evaluating levodopa carbidopa and entacapone (LCE) and Placebo for Cocaine Dependence. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The proposed study will look at cocaine dependent individuals and will consist of three consecutive phases: 1) the 2-week outpatient lead-in phase during which behavioral therapy will be administered; 2) the 15-21 day inpatient phase (during which participants will start study medication of levodopa,carbidopa and entacapone (LCE) and will undergo brain imaging and 3) the 24 weeks outpatient treatment trial. The purpose is to see if treatment with LCE may reverse baseline brain deficits and if this change is associated with clinical improvement. Hypothesis is that treatment with LCE, compared to placebo, increases abstinence from cocaine over a 12-week trial in combination with behavioral treatment with voucher incentives.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 9, 2011
Enrollment StartJul 1, 2014
Primary CompletionJul 1, 2014
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 14.6 years ago

Interventions

levodopa carbidopa and entacapone (LCE)drug

400mg/100mg/200mg, twice daily

Placebodrug

matched placebo for LCE condition dosed twice daily